董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Shai N. Gozani | 男 | Chairman of the Board, Chief Executive Officer, President and Secretary | 56 | 18.14万美元 | 15.38 | 2021-03-01 |
| David E. Goodman | 男 | Director | 64 | 3.88万美元 | 0.0026 | 2021-03-01 |
| Nancy E. Katz | 女 | Director | 61 | 3.30万美元 | 0.0026 | 2021-03-01 |
| David Van Avermaete | 男 | Director | 69 | 0.31万美元 | 未持股 | 2021-03-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Shai N. Gozani | 男 | Chairman of the Board, Chief Executive Officer, President and Secretary | 56 | 18.14万美元 | 15.38 | 2021-03-01 |
| Thomas T. Higgins | 男 | Senior Vice President, Chief Financial Officer and Treasurer | 69 | 23.74万美元 | 8.34 | 2021-03-01 |
董事简历
中英对照 | 中文 | 英文- Shai N. Gozani
-
Shai N. Gozani在1996年创建了公司，目前担任董事会总裁、总裁、首席执行官和秘书长。自1996年创建公司，Gozani先生在公司担任了一些职务，包括自1996年担任董事会总裁，von给1996年到1998年以及从2002年至今担任总裁，自1997年担任首席执行官，自2008年7月担任秘书长。Gozani先生从加州大学伯克利分校（University of California, Berkeley）获得计算机科学学士学位，生物工程博士学位和神经生物学博士学位。他还从哈佛大学医学院（Harvard Medical School）和麻省理工学院（M.I.T。）所属Harvard-M.I.T. Division of Health Sciences获得医学博士学位。在创建公司前，Gozani博士在哈佛大学医学院Gerald Fischbach博士的实验室完成了神经物理学研究生学习。Gozani博士在以下领域发表过文章，包括基础和临床神经物理学，生物工程以及计算机化学。
Shai N. Gozani founded our company in 1996 and currently serves as Chairman of our Board of Directors and as our President, Chief Executive Officer and Secretary. Since founding our company in 1996 Dr. Gozani has served in a number of positions at our company including Chairman since 1996 President from 1996 to 1998 and from 2002 to the present, Chief Executive Officer since 1997 and Secretary since July 2008. Dr. Gozani holds a B.A. in computer science, an M.S. in Biomedical Engineering and a Ph.D. in Neurobiology, from the University of California, Berkeley. He also received an M.D. from Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences at M.I.T. Prior to forming our company, Dr. Gozani completed a neurophysiology research fellowship in the laboratory of Dr. Gerald Fischbach at Harvard Medical School. Dr. Gozani has published articles in the areas of basic and clinical neurophysiology, biomedical engineering and computational chemistry. - Shai N. Gozani在1996年创建了公司，目前担任董事会总裁、总裁、首席执行官和秘书长。自1996年创建公司，Gozani先生在公司担任了一些职务，包括自1996年担任董事会总裁，von给1996年到1998年以及从2002年至今担任总裁，自1997年担任首席执行官，自2008年7月担任秘书长。Gozani先生从加州大学伯克利分校（University of California, Berkeley）获得计算机科学学士学位，生物工程博士学位和神经生物学博士学位。他还从哈佛大学医学院（Harvard Medical School）和麻省理工学院（M.I.T。）所属Harvard-M.I.T. Division of Health Sciences获得医学博士学位。在创建公司前，Gozani博士在哈佛大学医学院Gerald Fischbach博士的实验室完成了神经物理学研究生学习。Gozani博士在以下领域发表过文章，包括基础和临床神经物理学，生物工程以及计算机化学。
- Shai N. Gozani founded our company in 1996 and currently serves as Chairman of our Board of Directors and as our President, Chief Executive Officer and Secretary. Since founding our company in 1996 Dr. Gozani has served in a number of positions at our company including Chairman since 1996 President from 1996 to 1998 and from 2002 to the present, Chief Executive Officer since 1997 and Secretary since July 2008. Dr. Gozani holds a B.A. in computer science, an M.S. in Biomedical Engineering and a Ph.D. in Neurobiology, from the University of California, Berkeley. He also received an M.D. from Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences at M.I.T. Prior to forming our company, Dr. Gozani completed a neurophysiology research fellowship in the laboratory of Dr. Gerald Fischbach at Harvard Medical School. Dr. Gozani has published articles in the areas of basic and clinical neurophysiology, biomedical engineering and computational chemistry.
- David E. Goodman
-
David E. Goodman自2004年6月担任董事会成员。自2013年，Goodman博士担任FeetFirst的首席执行官，这是一家他联合创建的技术健康护理服务公司，该公司在加州和夏威夷有业务，该公司致力于防止对糖尿病人有巨大损伤同时需要巨额医药费的微脉管疗法的使用。自2012年，Goodman先生担任FirstVitals的首席医药官，这是一家关注于身体健康和疾病防控的健康护理公司。自2011年，Goodman博士担任SEDline, Inc.的总裁和首席执行官们这是一家以研究为导向的公司，其使命是扩大神经监测应用的使用范围。从2008年到2009年，Goodman先生担任Masimo Corporation所属业务开发部门的执行副总裁，这是一家非植入性病人监测设备制造商。从2006年到2008年，Goodman博士担任独立顾问，并向医疗设备和生物制药公司提供产品设计、管理和分析咨询服务，他还分别从2003年到2004年一家从2001年到2002年担任上述职务。从2005年到2006年，Goodman博士担任BaroSense, Inc.的总裁和首席执行官，这是一家医疗设备公司，该公司关注于长期治疗肥胖症的小型侵入型设备的开发。从2004年到2005年，Goodman博士担任Interventional Therapeutic Solutions, Inc.的总裁以及首席执行官，这是一家植入性药物系统公司。从2002年到2003年，Goodman先生担任Pherin Pharmaceuticals的董事会总裁、总裁和首席执行官，这是一家药物发明和开发公司。从1994年到2001年，Goodman先生但热各种职务，包括LifeMasters Supported SelfCare, Inc.的首席执行官、首席医药官和董事，这是一家疾病管理服务公司，他创建了该公司。Goodman先生还担任Sound Surgical Technologies LLC的董事，这是一家私人手术工具生产商，他从2011年任职到该公司在2013年被Solta Medical（纳斯达克（Nasdaq）代码：SLTM）。Goodman博士从宾夕法尼亚大学（University of Pennsylvania）获得应用科学和生物工程学士学位，以及生物工程硕士学位。他从哈佛大学医学院（Harvard Medical School）和Harvard-M.I.T。的健康科技部门获得医学博士学位。Goodman博士拥有18项专利，同时拥有加州和夏威夷的从业执照。
David E. Goodman has served as a member of our Board of Directors since June 2004. Since 2013 Dr. Goodman has been running his own independent primary care medical practice where he also manages the care of first responders police, fire, EMS injured in the line of duty. From 2013-2016 Dr. Goodman has served as CEO of FeetFirst, a technology-focused healthcare services company he co-founded that is committed to preventing the devastating and expensive microvascular complications of diabetes. From 2014 - 2016 Dr. Goodman served as a director of Xtant Medical (OTC QX: BONE), a comprehensive supplier of orthopedic and spine surgery products. From 2012 - 2015 Dr. Goodman served as CMO of FirstVitals, a healthcare services company focused on wellness and prevention. Since 2011 Dr. Goodman has also served as an independent consultant. During 2010 Dr. Goodman served as President and Chief Executive Officer of SEDline, Inc., a research-focused company with the mission to expand the scope and applications for neuromonitoring. From 2008 to 2009 Dr. Goodman served as Executive Vice President of Business Development for Masimo Corporation, a manufacturer of non-invasive patient monitors. From 2006 to 2008 Dr. Goodman served as an independent consultant providing product design, regulatory and analytical consulting services to medical device and biopharmaceutical companies and also served in this capacity from 2003 to 2004 and from 2001 to 2002. From 2005 to 2006 Dr. Goodman served as President and Chief Executive Officer of BaroSense, Inc., a medical device company focused on developing minimally invasive devices for the long-term treatment of obesity. From 2004 to 2005 Dr. Goodman served as President and Chief Executive Officer of Interventional Therapeutic Solutions, Inc., an implantable drug delivery systems company. From 2002 to 2003 Dr. Goodman served as Chairman, President and Chief Executive Officer of Pherin Pharmaceuticals, a pharmaceutical discovery and development company. From 1994 to 2001 Dr. Goodman held various positions, including Chief Executive Officer, Chief Medical Officer and director, for LifeMasters Supported SelfCare, Inc., a disease management services company that Dr. Goodman founded. Dr. Goodman also served as a director of Sound Surgical Technologies LLC, a private manufacturer of aesthetic surgical tools from 2011 until its acquisition by Solta Medical (Nasdaq:SLTM) in 2013. Dr. Goodman holds a B.A.S. in applied science and bioengineering and a M.S.E. in bioengineering from the University of Pennsylvania. He also received an M.D. from Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology. Dr. Goodman holds 22 issued and pending patents and is a practicing physician with licenses in California and Hawaii. - David E. Goodman自2004年6月担任董事会成员。自2013年，Goodman博士担任FeetFirst的首席执行官，这是一家他联合创建的技术健康护理服务公司，该公司在加州和夏威夷有业务，该公司致力于防止对糖尿病人有巨大损伤同时需要巨额医药费的微脉管疗法的使用。自2012年，Goodman先生担任FirstVitals的首席医药官，这是一家关注于身体健康和疾病防控的健康护理公司。自2011年，Goodman博士担任SEDline, Inc.的总裁和首席执行官们这是一家以研究为导向的公司，其使命是扩大神经监测应用的使用范围。从2008年到2009年，Goodman先生担任Masimo Corporation所属业务开发部门的执行副总裁，这是一家非植入性病人监测设备制造商。从2006年到2008年，Goodman博士担任独立顾问，并向医疗设备和生物制药公司提供产品设计、管理和分析咨询服务，他还分别从2003年到2004年一家从2001年到2002年担任上述职务。从2005年到2006年，Goodman博士担任BaroSense, Inc.的总裁和首席执行官，这是一家医疗设备公司，该公司关注于长期治疗肥胖症的小型侵入型设备的开发。从2004年到2005年，Goodman博士担任Interventional Therapeutic Solutions, Inc.的总裁以及首席执行官，这是一家植入性药物系统公司。从2002年到2003年，Goodman先生担任Pherin Pharmaceuticals的董事会总裁、总裁和首席执行官，这是一家药物发明和开发公司。从1994年到2001年，Goodman先生但热各种职务，包括LifeMasters Supported SelfCare, Inc.的首席执行官、首席医药官和董事，这是一家疾病管理服务公司，他创建了该公司。Goodman先生还担任Sound Surgical Technologies LLC的董事，这是一家私人手术工具生产商，他从2011年任职到该公司在2013年被Solta Medical（纳斯达克（Nasdaq）代码：SLTM）。Goodman博士从宾夕法尼亚大学（University of Pennsylvania）获得应用科学和生物工程学士学位，以及生物工程硕士学位。他从哈佛大学医学院（Harvard Medical School）和Harvard-M.I.T。的健康科技部门获得医学博士学位。Goodman博士拥有18项专利，同时拥有加州和夏威夷的从业执照。
- David E. Goodman has served as a member of our Board of Directors since June 2004. Since 2013 Dr. Goodman has been running his own independent primary care medical practice where he also manages the care of first responders police, fire, EMS injured in the line of duty. From 2013-2016 Dr. Goodman has served as CEO of FeetFirst, a technology-focused healthcare services company he co-founded that is committed to preventing the devastating and expensive microvascular complications of diabetes. From 2014 - 2016 Dr. Goodman served as a director of Xtant Medical (OTC QX: BONE), a comprehensive supplier of orthopedic and spine surgery products. From 2012 - 2015 Dr. Goodman served as CMO of FirstVitals, a healthcare services company focused on wellness and prevention. Since 2011 Dr. Goodman has also served as an independent consultant. During 2010 Dr. Goodman served as President and Chief Executive Officer of SEDline, Inc., a research-focused company with the mission to expand the scope and applications for neuromonitoring. From 2008 to 2009 Dr. Goodman served as Executive Vice President of Business Development for Masimo Corporation, a manufacturer of non-invasive patient monitors. From 2006 to 2008 Dr. Goodman served as an independent consultant providing product design, regulatory and analytical consulting services to medical device and biopharmaceutical companies and also served in this capacity from 2003 to 2004 and from 2001 to 2002. From 2005 to 2006 Dr. Goodman served as President and Chief Executive Officer of BaroSense, Inc., a medical device company focused on developing minimally invasive devices for the long-term treatment of obesity. From 2004 to 2005 Dr. Goodman served as President and Chief Executive Officer of Interventional Therapeutic Solutions, Inc., an implantable drug delivery systems company. From 2002 to 2003 Dr. Goodman served as Chairman, President and Chief Executive Officer of Pherin Pharmaceuticals, a pharmaceutical discovery and development company. From 1994 to 2001 Dr. Goodman held various positions, including Chief Executive Officer, Chief Medical Officer and director, for LifeMasters Supported SelfCare, Inc., a disease management services company that Dr. Goodman founded. Dr. Goodman also served as a director of Sound Surgical Technologies LLC, a private manufacturer of aesthetic surgical tools from 2011 until its acquisition by Solta Medical (Nasdaq:SLTM) in 2013. Dr. Goodman holds a B.A.S. in applied science and bioengineering and a M.S.E. in bioengineering from the University of Pennsylvania. He also received an M.D. from Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology. Dr. Goodman holds 22 issued and pending patents and is a practicing physician with licenses in California and Hawaii.
- Nancy E. Katz
-
Nancy E. Katz自2010年12月成为董事会一员。自2011年5月，Katz女士担任Medtronic, Inc.负责消费者市场营销的副总裁，这是一家医药技术公司。从2005年7月到2010年7月，Katz女士担任Bayer Diabetes Care- North America的高级副总裁。此前，她是Calypte Biomedical Corporation和Zila Pharmaceutical, Inc的总裁和首席执行官，前者是艾滋病诊断产品生产商，后者是口腔护理产品生产商。她还在以下公司担任高级市场营销职务，包括Johnson & Johnson所属Lifescan部门（研制血糖糖尿病产品）、Schering-Plough Healthcare Products和American Home Products。她此前任职于以下公司董事会，包括Neoprobe Corporation（美国证券交易所（AMEX）代码：NEOP）董事会，Calypte Biomedical Corporation, LXN Corporation和Pepgen Corporation。她从南佛罗里达大学（University of South Florida）获得商学学士学位。
Nancy E. Katz was appointed to the Board of Directors of the Company in October 2016. Ms. Katz served as Vice President, Consumer Marketing at Medtronic, Inc., a medical technology company, from May 2011 to August 2014. From July 2005 to July 2010 Ms. Katz was Senior Vice President, Bayer Diabetes Care - North America. Prior to this position, she was President and Chief Executive Officer of Calypte Biomedical Corporation, a manufacturer of HIV diagnostics, President of Zila Pharmaceutical, Inc., a manufacturer of oral care products, and held senior marketing positions with the Lifescan division of Johnson & Johnson blood glucose diabetes products, Schering-Plough Healthcare Products, and with American Home Products. She has previously served on the Boards of Directors of Neoprobe Corporation, Calypte Biomedical Corporation, LXN Corporation and Pepgen Corporation. She currently serves on the Board of NeuroMetrix, Inc. She received a B.S. in business from the University of South Florida. Ms. Katz is a member of the Audit Committee and the Nominating and Corporate Governance Committee. - Nancy E. Katz自2010年12月成为董事会一员。自2011年5月，Katz女士担任Medtronic, Inc.负责消费者市场营销的副总裁，这是一家医药技术公司。从2005年7月到2010年7月，Katz女士担任Bayer Diabetes Care- North America的高级副总裁。此前，她是Calypte Biomedical Corporation和Zila Pharmaceutical, Inc的总裁和首席执行官，前者是艾滋病诊断产品生产商，后者是口腔护理产品生产商。她还在以下公司担任高级市场营销职务，包括Johnson & Johnson所属Lifescan部门（研制血糖糖尿病产品）、Schering-Plough Healthcare Products和American Home Products。她此前任职于以下公司董事会，包括Neoprobe Corporation（美国证券交易所（AMEX）代码：NEOP）董事会，Calypte Biomedical Corporation, LXN Corporation和Pepgen Corporation。她从南佛罗里达大学（University of South Florida）获得商学学士学位。
- Nancy E. Katz was appointed to the Board of Directors of the Company in October 2016. Ms. Katz served as Vice President, Consumer Marketing at Medtronic, Inc., a medical technology company, from May 2011 to August 2014. From July 2005 to July 2010 Ms. Katz was Senior Vice President, Bayer Diabetes Care - North America. Prior to this position, she was President and Chief Executive Officer of Calypte Biomedical Corporation, a manufacturer of HIV diagnostics, President of Zila Pharmaceutical, Inc., a manufacturer of oral care products, and held senior marketing positions with the Lifescan division of Johnson & Johnson blood glucose diabetes products, Schering-Plough Healthcare Products, and with American Home Products. She has previously served on the Boards of Directors of Neoprobe Corporation, Calypte Biomedical Corporation, LXN Corporation and Pepgen Corporation. She currently serves on the Board of NeuroMetrix, Inc. She received a B.S. in business from the University of South Florida. Ms. Katz is a member of the Audit Committee and the Nominating and Corporate Governance Committee.
- David Van Avermaete
-
David Van Avermaete自2013年9月成为董事会一员。从2004年4月到2013年2月担任VeraLight, Inc.的首席执行官，这是一家他创建的医疗设备公司，该公司关注于二型糖尿病的非侵入幸监测。从2000年到2004年，Van Avermaete的担任InLight Solutions负责非侵入技术的高级副总裁，这是一家关注于糖尿病领域颠覆性技术的公司。从1998年到2000年，Van Avermaete先生担任Johnson & Johnson所属LifeScan部门到的美国总裁，从1990年到1998年在LifeScan担任各种高级职务，主要关注于销售和市场营销。此前，Van Avermaete先生担任Biotope负责销售和市场营销的副总裁；Roche Diagnostics负责市场营销的董事；Syntex Medical Diagnostics负责市场营销和销售的董事。Van Avermaete先生从亚利桑那大学（University of Arizona）获得工商管理学硕士学位和微生物学硕士学位，从波尔州立大学（Ball State University）获得医疗技术和化学硕士学位。
David Van Avermaete has served as a member of our Board of Directors since September 2013. Since January 2015 Mr. Van Avermaete has served as President of Inject Safe Technologies, a privately held company that has developed a bandage specifically designed to support injections. From April 2004 to February 2013 Mr. Van Avermaete served as Chief Executive Officer of VeraLight, Inc., a medical device company he founded, that focuses on non-invasive screening for type 2 diabetes. From 2000 to 2004 Mr. Van Avermaete served as Senior Vice President Non-Invasive Technology of InLight Solutions, a Johnson & Johnson company focused on transformational technology in the diabetes field. From 1998 to 2000 Mr. Van Avermaete served as U.S. President of the LifeScan division of Johnson & Johnson and, from 1990 to 1998 in various senior level positions at LifeScan concentrating in sales and marketing. Previously, Mr. Van Avermaete served as Vice President Sales and Marketing at Biotope, Director of Marketing at Roche Diagnostics, and Director of Marketing and Sales at Syntex Medical Diagnostics. Mr. Van Avermaete received a Master of Business Administration and a Master of Science Degree in Microbiology from the University of Arizona and a Bachelor of Science Degree in medical technology and chemistry from Ball State University. - David Van Avermaete自2013年9月成为董事会一员。从2004年4月到2013年2月担任VeraLight, Inc.的首席执行官，这是一家他创建的医疗设备公司，该公司关注于二型糖尿病的非侵入幸监测。从2000年到2004年，Van Avermaete的担任InLight Solutions负责非侵入技术的高级副总裁，这是一家关注于糖尿病领域颠覆性技术的公司。从1998年到2000年，Van Avermaete先生担任Johnson & Johnson所属LifeScan部门到的美国总裁，从1990年到1998年在LifeScan担任各种高级职务，主要关注于销售和市场营销。此前，Van Avermaete先生担任Biotope负责销售和市场营销的副总裁；Roche Diagnostics负责市场营销的董事；Syntex Medical Diagnostics负责市场营销和销售的董事。Van Avermaete先生从亚利桑那大学（University of Arizona）获得工商管理学硕士学位和微生物学硕士学位，从波尔州立大学（Ball State University）获得医疗技术和化学硕士学位。
- David Van Avermaete has served as a member of our Board of Directors since September 2013. Since January 2015 Mr. Van Avermaete has served as President of Inject Safe Technologies, a privately held company that has developed a bandage specifically designed to support injections. From April 2004 to February 2013 Mr. Van Avermaete served as Chief Executive Officer of VeraLight, Inc., a medical device company he founded, that focuses on non-invasive screening for type 2 diabetes. From 2000 to 2004 Mr. Van Avermaete served as Senior Vice President Non-Invasive Technology of InLight Solutions, a Johnson & Johnson company focused on transformational technology in the diabetes field. From 1998 to 2000 Mr. Van Avermaete served as U.S. President of the LifeScan division of Johnson & Johnson and, from 1990 to 1998 in various senior level positions at LifeScan concentrating in sales and marketing. Previously, Mr. Van Avermaete served as Vice President Sales and Marketing at Biotope, Director of Marketing at Roche Diagnostics, and Director of Marketing and Sales at Syntex Medical Diagnostics. Mr. Van Avermaete received a Master of Business Administration and a Master of Science Degree in Microbiology from the University of Arizona and a Bachelor of Science Degree in medical technology and chemistry from Ball State University.
高管简历
中英对照 | 中文 | 英文- Shai N. Gozani
Shai N. Gozani在1996年创建了公司，目前担任董事会总裁、总裁、首席执行官和秘书长。自1996年创建公司，Gozani先生在公司担任了一些职务，包括自1996年担任董事会总裁，von给1996年到1998年以及从2002年至今担任总裁，自1997年担任首席执行官，自2008年7月担任秘书长。Gozani先生从加州大学伯克利分校（University of California, Berkeley）获得计算机科学学士学位，生物工程博士学位和神经生物学博士学位。他还从哈佛大学医学院（Harvard Medical School）和麻省理工学院（M.I.T。）所属Harvard-M.I.T. Division of Health Sciences获得医学博士学位。在创建公司前，Gozani博士在哈佛大学医学院Gerald Fischbach博士的实验室完成了神经物理学研究生学习。Gozani博士在以下领域发表过文章，包括基础和临床神经物理学，生物工程以及计算机化学。
Shai N. Gozani founded our company in 1996 and currently serves as Chairman of our Board of Directors and as our President, Chief Executive Officer and Secretary. Since founding our company in 1996 Dr. Gozani has served in a number of positions at our company including Chairman since 1996 President from 1996 to 1998 and from 2002 to the present, Chief Executive Officer since 1997 and Secretary since July 2008. Dr. Gozani holds a B.A. in computer science, an M.S. in Biomedical Engineering and a Ph.D. in Neurobiology, from the University of California, Berkeley. He also received an M.D. from Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences at M.I.T. Prior to forming our company, Dr. Gozani completed a neurophysiology research fellowship in the laboratory of Dr. Gerald Fischbach at Harvard Medical School. Dr. Gozani has published articles in the areas of basic and clinical neurophysiology, biomedical engineering and computational chemistry.- Shai N. Gozani在1996年创建了公司，目前担任董事会总裁、总裁、首席执行官和秘书长。自1996年创建公司，Gozani先生在公司担任了一些职务，包括自1996年担任董事会总裁，von给1996年到1998年以及从2002年至今担任总裁，自1997年担任首席执行官，自2008年7月担任秘书长。Gozani先生从加州大学伯克利分校（University of California, Berkeley）获得计算机科学学士学位，生物工程博士学位和神经生物学博士学位。他还从哈佛大学医学院（Harvard Medical School）和麻省理工学院（M.I.T。）所属Harvard-M.I.T. Division of Health Sciences获得医学博士学位。在创建公司前，Gozani博士在哈佛大学医学院Gerald Fischbach博士的实验室完成了神经物理学研究生学习。Gozani博士在以下领域发表过文章，包括基础和临床神经物理学，生物工程以及计算机化学。
- Shai N. Gozani founded our company in 1996 and currently serves as Chairman of our Board of Directors and as our President, Chief Executive Officer and Secretary. Since founding our company in 1996 Dr. Gozani has served in a number of positions at our company including Chairman since 1996 President from 1996 to 1998 and from 2002 to the present, Chief Executive Officer since 1997 and Secretary since July 2008. Dr. Gozani holds a B.A. in computer science, an M.S. in Biomedical Engineering and a Ph.D. in Neurobiology, from the University of California, Berkeley. He also received an M.D. from Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences at M.I.T. Prior to forming our company, Dr. Gozani completed a neurophysiology research fellowship in the laboratory of Dr. Gerald Fischbach at Harvard Medical School. Dr. Gozani has published articles in the areas of basic and clinical neurophysiology, biomedical engineering and computational chemistry.
- Thomas T. Higgins
Thomas T. Higgins自2009年9月担任高级副总裁、首席财务官和财务主管。在加入NeuroMetrix前，从2005年1月到2008年3月，Higgins先生是Caliper Life Sciences, Inc的执行副总裁和首席财务官，这是一家为生命科学研究提供技术支持和服务的提供商。在加入Caliper前，Higgins先生是V.I. Technologies, Inc.（Vitex）的负责运营的执行副总裁以及首席财务官，这是一家致力于解决血液安全的生物技术公司。在加入Vitex前，Higgins先生担任Cabot Corporation一些高级金融和运营职务。他在Cabot担任的最后的职务是Distrigas of Massachusetts Corporation的总裁，这是一家从事液态天然气业务的子公司，此前，他是Cabot所属亚太地区炭黑业务的副总裁和总经理。在加入Cabot前，Higgins先生任职于Pricewaterhouse Coopers，他从这家公司开始了他的职业生涯。Higgins先生从波士顿大学（Boston University）以优异成绩获得学士学位。
Thomas T. Higgins has served as our Senior Vice President, Chief Financial Officer and Treasurer since September 2009. Prior to joining NeuroMetrix, from January 2005 to March 2008 Mr. Higgins was Executive Vice President and Chief Financial Officer at Caliper Life Sciences, Inc., a provider of technology and services for life sciences research. Before Caliper, Mr. Higgins was Executive Vice President, Operations and Chief Financial Officer at V.I. Technologies, Inc. Vitex, a biotechnology company addressing blood safety. Before Vitex, Mr. Higgins served at Cabot Corporation in various senior finance and operations roles. His last position at Cabot was President of Distrigas of Massachusetts Corporation, a subsidiary involved in the liquefied natural gas business, and prior to that he was Vice President and General Manager of Cabot's Asia Pacific carbon black operations. Before joining Cabot, Mr. Higgins was with PricewaterhouseCoopers where he started his career. Mr. Higgins holds a BBA with honors from Boston University.- Thomas T. Higgins自2009年9月担任高级副总裁、首席财务官和财务主管。在加入NeuroMetrix前，从2005年1月到2008年3月，Higgins先生是Caliper Life Sciences, Inc的执行副总裁和首席财务官，这是一家为生命科学研究提供技术支持和服务的提供商。在加入Caliper前，Higgins先生是V.I. Technologies, Inc.（Vitex）的负责运营的执行副总裁以及首席财务官，这是一家致力于解决血液安全的生物技术公司。在加入Vitex前，Higgins先生担任Cabot Corporation一些高级金融和运营职务。他在Cabot担任的最后的职务是Distrigas of Massachusetts Corporation的总裁，这是一家从事液态天然气业务的子公司，此前，他是Cabot所属亚太地区炭黑业务的副总裁和总经理。在加入Cabot前，Higgins先生任职于Pricewaterhouse Coopers，他从这家公司开始了他的职业生涯。Higgins先生从波士顿大学（Boston University）以优异成绩获得学士学位。
- Thomas T. Higgins has served as our Senior Vice President, Chief Financial Officer and Treasurer since September 2009. Prior to joining NeuroMetrix, from January 2005 to March 2008 Mr. Higgins was Executive Vice President and Chief Financial Officer at Caliper Life Sciences, Inc., a provider of technology and services for life sciences research. Before Caliper, Mr. Higgins was Executive Vice President, Operations and Chief Financial Officer at V.I. Technologies, Inc. Vitex, a biotechnology company addressing blood safety. Before Vitex, Mr. Higgins served at Cabot Corporation in various senior finance and operations roles. His last position at Cabot was President of Distrigas of Massachusetts Corporation, a subsidiary involved in the liquefied natural gas business, and prior to that he was Vice President and General Manager of Cabot's Asia Pacific carbon black operations. Before joining Cabot, Mr. Higgins was with PricewaterhouseCoopers where he started his career. Mr. Higgins holds a BBA with honors from Boston University.